Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
46 studies found for:    " June 08, 2011":" July 08, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Completed Non-interventional Study on Use of Darunavir With Ritonavir in Clinical Practice
Condition: HIV Infections
Intervention: Drug: darunavir/ritonavir plus background regimen
22 Active, not recruiting Jail-Based Impact of Crime Intervention
Conditions: Substance Abuse;   HIV Risk;   Criminogenic Thinking;   Shame;   Guilt;   Empathy
Interventions: Behavioral: MI plus IOC group intervention;   Behavioral: Motivational Interview only
23 Not yet recruiting Victim Impact Modules for Jail Inmates
Conditions: Substance Abuse;   HIV Risk;   Shame;   Guilt;   Empathy;   Criminogenic Thinking
Interventions: Behavioral: Impact of Crime Modules;   Behavioral: TAU
24 Active, not recruiting HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Condition: Human Immunodeficiency Virus-1
Interventions: Drug: BMS-663068;   Drug: Raltegravir;   Drug: Tenofovir;   Drug: Ritonavir;   Drug: Atazanavir
25 Unknown  Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals
Conditions: Influenza, Human;   Human Immunodeficiency Virus I Infection
Intervention:
26 Active, not recruiting Evaluation of Re-Entry Values and Mindfulness Program (REVAMP) With Jail Inmates
Conditions: Impulsive Behavior;   Substance Abuse;   HIV Risk Behavior;   Anxiety;   Depression;   Criminogenic Thinking
Interventions: Behavioral: REVAMP;   Behavioral: TAU
27 Completed Immune Responses to Two Experimental HIV Vaccines in Healthy Adults
Conditions: HIV Negative;   Adaptive Immunity;   Innate Immunity
Interventions: Biological: VRC-HIVDNA016-00-VP;   Biological: VRC-HIVADV014-00-VP
28 Completed
Has Results
Multicountry, Multicenter Post-Marketing Observational Study of Clinical, Biological and Virological Outcomes, Compliance and Tolerability of Kaletra® in Routine Clinical Use
Condition: HIV-1 Patients
Intervention:
29 Unknown  GePheRal: Clinical Validation of the Genotypic Diagnosis of Hiv-1 Resistance to Raltegravir by Parallel Analysis of the Genotype and Phenotype Profiles of Resistance
Conditions: HIV-1 Infected Patients;   Fold-change Resistance;   Resistance Mutations
Intervention:
30 Active, not recruiting Maraviroc Switch Collaborative Study
Condition: HIV
Intervention: Drug: Maraviroc
31 Completed Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics
Condition: HIV
Intervention: Drug: zidovudine 300mg and lamivudine 150mg as Combivir
32 Recruiting Naltrexone for Medication Compliance Among HIV-infected Men With Alcohol Use Disorder
Conditions: HIV;   Alcohol Use Disorder
Interventions: Drug: oral naltrexone;   Drug: Placebo pill
33 Unknown  HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies
Condition: HIV
Interventions: Behavioral: Monetary Incentive;   Behavioral: Questionnaire Timing;   Behavioral: HIV Test Offering
34 Completed Increasing Viral Testing in the Emergency Department
Conditions: Drug Use;   HIV;   Hepatitis C
Intervention: Behavioral: Brief motivational intervention
35 Completed Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults
Conditions: HIV;   Human Papillomavirus
Interventions: Biological: Gardasil;   Biological: Cervarix
36 Completed Residual Risk Assessment Of HIV Transmission
Condition: HIV Infection
Intervention: Biological: blood and semen sampling, specific biological exams and biobank and self administered questionnaires
37 Active, not recruiting REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
Condition: HIV Infection
Interventions: Drug: Atripla (r);   Drug: Efavirenz;   Drug: Truvada;   Drug: Rifampin/isoniazid/pyrazinamide/ethambutol FDC;   Drug: Rifampin/isoniazid FDC
38 Completed Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Condition: HIV Infection
Intervention:
39 Completed Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers
Condition: HIV Infections
Interventions: Drug: Darunavir;   Drug: Ritonavir;   Drug: BI 201335
40 Completed Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials
Condition: HIV Infections
Interventions: Biological: Sub C gp140 Vaccine;   Biological: MF59C.1 Adjuvant

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-46) Show next page of results    Last Page
Indicates status has not been verified in more than two years